We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current LOVE market cap is 76.52M. The company's latest EPS is CAD 0.0715 and P/E is 11.89.
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 2.6M | 17.29M | 36.01M | 57.56M | 82.15M |
| Operating Income | -10.14M | -287k | 2.53M | 6.45M | 5.72M |
| Net Income | -12.48M | -1.53M | 2.31M | 6.95M | 6.44M |
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 54.85M | 92.02M | 125.62M | 141.52M | 154.72M |
| Total Liabilities | 16.49M | 27.91M | 58.88M | 61.78M | 66.77M |
| Total Equity | 38.37M | 64.12M | 66.74M | 79.74M | 87.95M |
| Year End 31 August 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -9.33M | -2.09M | -6.08M | 5.44M | 10.68M |
| Investing | -8.55M | -30.83M | -15.35M | -9.48M | -5.19M |
| Financing | -915k | 33.25M | 25.46M | -3.72M | -3.14M |
| Market Cap | 76.52M |
| Price to Earnings Ratio | 11.89 |
| Price to Sales Ratio | 0.93 |
| Price to Cash Ratio | 11.56 |
| Price to Book Ratio | 0.87 |
| Dividend Yield | - |
| Shares Outstanding | 90.02M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.03 (3.41%) |
| Company Name | Cannara Biotech Inc |
| Address |
333 d��carie, suite 200 saint-laurent, quebec H4N 3M9 |
| Website | https://www.cannara.ca |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
